LncRNA CCAT2 promotes malignant progression of metastatic gastric cancer through regulating CD44 alternative splicing
ConclusionsOur findings identified a novel mechanism by which lncRNA CCAT2, as a type of protein-binding RNA,
regulates alternative splicing of CD44 and promotes GC progression. This axis may become an effective target for clinical diagnosis and treatment. (Source: Cellular Oncology)
Source: Cellular Oncology - June 24, 2023 Category: Cancer & Oncology Source Type: research
LncRNA MIR4435-2HG drives cancer progression by modulating cell cycle regulators and mTOR signaling in stroma-enriched subtypes of urothelial carcinoma of the bladder
ConclusionsOur data indicate that upregulated MIR4435-2HG expression levels are significantly correlated with a poor prognosis of UCB patients. MIR4435-2HG promotes bladder cancer progression, mediates cell cycle (de)regulation and modulates mTOR signaling. MIR4435-2HG is an oncogenic lncRNA in UCB that may serve as a diagnostic and therapeutic target. (Source: Cellular Oncology)
Source: Cellular Oncology - June 24, 2023 Category: Cancer & Oncology Source Type: research
Competition between p53 and YY1 determines PHGDH expression and malignancy in bladder cancer
ConclusionYY1 drives PHGDH expression in the context of mutant p53 and promotes bladder tumorigenesis, which preliminarily explains the relationship between high-frequency mutations of p53 and dysfunctional serine metabolism in bladder cancer. (Source: Cellular Oncology)
Source: Cellular Oncology - June 16, 2023 Category: Cancer & Oncology Source Type: research
Methionine-producing tumor micro(be) environment fuels growth of solid tumors
In this study, we focused on methionine as one of the critical molecules, but we also hypothesize that additional bacterial metabolites may also be utilized by LUAD. Indeed, our radiolabeling data suggest that other biomolecules are shared between cancer cells and bacteria. Thus, modulating the local microbiome may have an indirect effect on tumor development, progression, and metastasis. (Source: Cellular Oncology)
Source: Cellular Oncology - June 15, 2023 Category: Cancer & Oncology Source Type: research
Iron metabolism in colorectal cancer: a balancing act
Conclusions and perspectivesThis review addresses the complex role of iron in CRC, particularly in what concerns the consequences of iron excess or deprivation in tumor development and progression. We also dissect the regulation of cellular iron metabolism in the CRC microenvironment and emphasize the role of hypoxia and of oxidative stress (e.g. ferroptosis) in CRC. Finally, we underline some iron-related players as potential therapeutic targets against CRC malignancy. (Source: Cellular Oncology)
Source: Cellular Oncology - June 5, 2023 Category: Cancer & Oncology Source Type: research
Clostridium butyricum and its metabolite butyrate promote ferroptosis susceptibility in pancreatic ductal adenocarcinoma
ConclusionOur study reveals a novel antitumor mechanism of butyrate and suggests the therapeutic potential of butyrate-producing probiotics in PDAC. (Source: Cellular Oncology)
Source: Cellular Oncology - June 1, 2023 Category: Cancer & Oncology Source Type: research
Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphoma
ConclusionIn summary, the results of the present study suggest that LEN can improve the function of CD19-CAR-T cells, providing a basis for clinical trials using this combination therapy against DLBCL. (Source: Cellular Oncology)
Source: Cellular Oncology - May 23, 2023 Category: Cancer & Oncology Source Type: research
METTL3 suppresses pancreatic ductal adenocarcinoma progression through activating endogenous dsRNA-induced anti-tumor immunity
ConclusionOur findings indicate that tumor cell-intrinsic m6A modification participates in the regulation of tumor immune landscape. Adjusting the m6A level may be an effective strategy to overcome the resistance to immunotherapy and increase responsiveness to immunotherapy in PDAC. (Source: Cellular Oncology)
Source: Cellular Oncology - May 13, 2023 Category: Cancer & Oncology Source Type: research
Single-cell RNA sequencing reveals the cellular and molecular characteristics of high-grade and metastatic bladder cancer
ConclusionThis study through scRNA-seq enhanced our understanding of new features about the cellular and molecular similarities and differences of high-grade and metastatic bladder cancer, which might provide potential therapeutic targets in future treatment. (Source: Cellular Oncology)
Source: Cellular Oncology - May 11, 2023 Category: Cancer & Oncology Source Type: research
MAP3K1 expression is associated with progression and poor prognosis of hormone receptor-positive, HER2-negative early-stage breast cancer
ConclusionOur results indicate that the overexpression of MAP3K1 plays a major role in the poor prognosis of HR-positive, HER2-negative early stage breast cancer. (Source: Cellular Oncology)
Source: Cellular Oncology - May 11, 2023 Category: Cancer & Oncology Source Type: research
A novel pyroptosis-associated lncRNA LINC01133 promotes pancreatic adenocarcinoma development via miR-30b-5p/SIRT1 axis
ConclusionWith significant prognostic value, our PRL signature are involved in the biological processes of PAAD cells and associated with the immune environment. LINC01133 suppresses pyroptosis to promote PAAD development and could serve as a potential target for PAAD treatment. (Source: Cellular Oncology)
Source: Cellular Oncology - May 4, 2023 Category: Cancer & Oncology Source Type: research
PAQR5 inhibits the growth and metastasis of clear cell renal cell carcinoma by suppressing the JAK/STAT3 signaling pathway
ConclusionOur study revealed the tumor suppressor role of PAQR5 in ccRCC. PAQR5 is a valuable prognostic biomarker for ccRCC and may provide new strategies for clinical targeted therapy. (Source: Cellular Oncology)
Source: Cellular Oncology - May 1, 2023 Category: Cancer & Oncology Source Type: research
Non-canonical role for the ataxia-telangiectasia-Rad3 pathway in STAT3 activation in human multiple myeloma cells
ConclusionsCollectively, these findings argue for a non-canonical role for the ATR kinase in STAT3 activation in MM cells, and suggest that STAT3 inactivation contributes to the lethal actions of ATR inhibitors in MM. (Source: Cellular Oncology)
Source: Cellular Oncology - May 1, 2023 Category: Cancer & Oncology Source Type: research
Repurposing ketotifen as a therapeutic strategy for neuroendocrine prostate cancer by targeting the IL-6/STAT3 pathway
ConclusionOur findings repurpose ketotifen for antitumor applications and endorse its clinical development for NEPC therapy, offering a novel and promising therapeutic strategy for this formidable cancer subtype. (Source: Cellular Oncology)
Source: Cellular Oncology - April 29, 2023 Category: Cancer & Oncology Source Type: research
SYVN1 ubiquitinates FoxO1 to induce β-catenin nuclear translocation, PD-L1-mediated metastasis, and immune evasion of hepatocellular carcinoma
ConclusionSYVN1 regulates FoxO1 ubiquitination to stimulate β-catenin nuclear translocation and promotes PD-L1-mediated metastasis and immune evasion in HCC. (Source: Cellular Oncology)
Source: Cellular Oncology - April 26, 2023 Category: Cancer & Oncology Source Type: research
